SARS-CoV-2 Spike Protein Intensifies Cerebrovascular Complications in Diabetic HACE2 Mice Through RAAS and TLR Signaling Activation
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Diabetics are more vulnerable to SARS-CoV-2 neurological manifestations. The molecular mechanisms of SARS-CoV-2-induced cerebrovascular dysfunction in diabetes are unclear. We hypothesize that SARS-CoV-2 exacerbates diabetes-induced cerebrovascular oxidative stress and inflammation via activation of the destructive arm of the renin-angiotensin-aldosterone system (RAAS) and Toll-like receptor (TLR) signaling. SARS-CoV-2 spike protein was injected in humanized ACE2 transgenic knock-in mice. Cognitive functions, cerebral blood flow, cerebrovascular architecture, RAAS, and TLR signaling were used to determine the effect of SARS-CoV-2 spike protein in diabetes. Studies were mirrored in vitro using human brain microvascular endothelial cells treated with high glucose-conditioned media to mimic diabetic conditions. Spike protein exacerbated diabetes-induced cerebrovascular oxidative stress, inflammation, and endothelial cell death resulting in an increase in vascular rarefaction and diminished cerebral blood flow. SARS-CoV-2 spike protein worsened cognitive dysfunction in diabetes compared to control mice. Spike protein enhanced the destructive RAAS arm at the expense of the RAAS protective arm. In parallel, spike protein significantly exacerbated TLR signaling in diabetes, aggravating inflammation and cellular apoptosis vicious circle. Our study illustrated that SAR-CoV-2 spike protein intensified RAAS and TLR signaling in diabetes, increasing cerebrovascular damage and cognitive dysfunction.
Acioglu C, Elkabes S J Neuroinflammation. 2025; 22(1):39.
PMID: 39955600 PMC: 11829548. DOI: 10.1186/s12974-025-03360-3.
Heath S, Hermanns V, Coucha M, Abdelsaid M Transl Stroke Res. 2024; .
PMID: 39354270 DOI: 10.1007/s12975-024-01301-5.
Special Issue "The Role of Toll-Like Receptors (TLRs) in Infection and Inflammation 2.0".
Kircheis R, Planz O Int J Mol Sci. 2024; 25(17).
PMID: 39273656 PMC: 11396464. DOI: 10.3390/ijms25179709.
Meier M, Becker S, Levine E, DuFresne O, Foster K, Moore J PLoS One. 2024; 19(7):e0304135.
PMID: 39074114 PMC: 11285960. DOI: 10.1371/journal.pone.0304135.
Valencia I, Lumpuy-Castillo J, Magalhaes G, Sanchez-Ferrer C, Lorenzo O, Peiro C Cardiovasc Diabetol. 2024; 23(1):75.
PMID: 38378550 PMC: 10880237. DOI: 10.1186/s12933-023-02097-8.